SEC Filing Summary: AspenBio Pharma, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AspenBio Pharma, Inc. on May 24, 2012, reporting events occurring on May 23, 2012. The filing discloses the appointment of a new senior executive officer and the terms of his employment agreement. Note: The request metadata referenced "Riot Platforms, Inc.", but the source text explicitly identifies the registrant as AspenBio Pharma, Inc.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation details:
- Base Salary: $230,000 annually.
- Incentive Plan Target: 35% of annual base salary.
- Severance: Six months of base salary upon termination without cause, death, or disability (after 60 days of employment).
- Stock Options: 120,000 non-qualified options at an exercise price of $0.57 per share.
Material Changes
The primary material change is the appointment of Donald R. Hurd as Senior Vice President and Chief Commercial Officer. Mr. Hurd brings over 30 years of experience in the in vitro diagnostics industry, having previously served as Vice President of Sales at BioBehavioral Diagnostics and held leadership roles at MicroPhage, Siemens Healthcare Diagnostics, and Bayer Healthcare Diagnostics.
Outlook, Risks, and Unusual Items
Employment Terms: The stock options vest 50% at the six-month anniversary of the grant date, with the remaining balance vesting monthly over the subsequent six months. Unvested options accelerate upon a "Change in Control." The options are exercisable for 10 years.
Unusual Items: The stock option grant is an employment-inducement grant made outside of the Company's 2002 Stock Incentive Plan.
Risks/Contingencies: The filing does not disclose specific financial risks or contingencies beyond standard employment termination clauses.
Investor Verification Checklist
- Verify the exact vesting schedule and acceleration triggers for the 120,000 stock options granted to Mr. Hurd.
- Confirm the impact of this new executive appointment on the company's commercial strategy and sales pipeline.
- Review the full text of the Executive Employment Agreement (Exhibit 10.1) for additional restrictive covenants or performance metrics.
- Check subsequent filings for any updates to the company's financial position, as this 8-K contains no financial statements.